Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS).
Official Title
A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS)
Keywords
Multiple Sclerosis, CC-97540, CAR T, CART, NEX T, NEXT, BMS-986353, RMS, PMS, RRMS, aSPMS, PPMS, iSPMS, Sclerosis, Cyclophosphamide, Fludarabine